Organicell Regenerative Medicine, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Organicell Regenerative Medicine, Inc. engages in the development and commercialization of innovative biological therapeutics primarily focused on regenerative medicine. The company manufactures a range of products derived from perinatal sources that retain naturally occurring exosomes, hyaluronic acid, growth factors, proteins, and microRNAs without any additives or diluents. Its main products include Zofin™, an acellular biologic therapeutic targeting degenerative diseases and inflammatory conditions, and Patient Pure X™ (PPX™), an autologous blood-derived platform consisting of nanoparticle fractions derived from a patient's own peripheral blood aimed at promoting tissue healing and reducing inflammation for both medical and aesthetic applications. Organicell’s products are designed for use in regenerative therapies spanning orthopedics, immunology, cardiology, and aesthetics, addressing conditions such as COVID-19-related symptoms, osteoarthritis, chronic obstructive pulmonary disease, and tissue repair. Recent major developments include the company’s rebranding to ZEO ScientifiX in early 2024, reflecting an expanded focus on advanced molecular biology, stem cell therapy, and regenerative medicine technologies. Organicell closed a $5.5 million funding round in 2022 to support technology platform development, clinical trial advancement, and vertical integration of production capabilities. The company has advanced clinical research for its lead products, including FDA approval for multiple Emergency Investigational New Drug Applications (eINDs) and Phase I/II trials investigating Zofin™ in indications such as Long COVID, COPD, and osteoarthritis. It also received Institutional Review Board approval in late 2022 to evaluate the safety of intravenous and intra-articular administration of PPX™ and plans to initiate Phase II efficacy studies pending regulatory approval and capital availability. Founded in 2014 and headquartered in Miami, Florida, Organicell operates as a clinical-stage biopharmaceutical entity targeting the global regenerative medicine market through medical providers and aesthetic clinics. The company’s proprietary biologics leverage autologous and perinatal sources to develop safe, bioactive therapeutics that promote cellular regeneration and inflammation control. Organicell’s strategic alliances, funding initiatives, and product innovations underpin its mission to offer novel, effective regenerative therapies for degenerative and inflammatory diseases, with ongoing clinical development programs and expanding commercial platforms supporting its growth trajectory in North America and potentially other international markets.
Organicell Regenerative Medicine (OTCMKTS:BPSR) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Organicell Regenerative Medicine (OTCMKTS:BPSR) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
Organicell Regenerative Medicine (OTCMKTS:BPSR) Shares Cross Below 50 Day Moving Average – Should You Sell?
Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™
Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan
Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential
‘Frontiers in Medicine' Publishes Organicell's Case Report Demonstrating the Use of Zofin™ in the Treatment of COVID-19 Patients
Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?